CureVac (NASDAQ:CVAC) Shares Gap Up – Should You Buy?

CureVac (NASDAQ:CVAC)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $3.40, but opened at $3.68. CureVac shares last traded at $3.71, with a volume of 261,665 shares traded.

Analysts Set New Price Targets

Several analysts have commented on the stock. JMP Securities restated a “market outperform” rating and set a $16.00 price objective on shares of CureVac in a research note on Friday, February 14th. UBS Group reduced their target price on shares of CureVac from $13.00 to $12.00 and set a “buy” rating for the company in a report on Wednesday.

CureVac Trading Up 4.7 %

The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.05. The firm has a market cap of $798.64 million, a price-to-earnings ratio of 6.47 and a beta of 2.48. The company has a fifty day moving average price of $3.06 and a 200-day moving average price of $3.19.

CureVac (NASDAQ:CVAC) last released its quarterly earnings data on Thursday, April 10th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The company had revenue of $15.44 million during the quarter, compared to analysts’ expectations of $6.40 million. CureVac had a return on equity of 21.98% and a net margin of 20.72%. As a group, research analysts expect that CureVac will post 0.72 EPS for the current year.

Institutional Trading of CureVac

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ballentine Partners LLC boosted its stake in shares of CureVac by 81.8% during the 1st quarter. Ballentine Partners LLC now owns 31,573 shares of the company’s stock worth $88,000 after acquiring an additional 14,210 shares in the last quarter. Greenleaf Trust purchased a new position in CureVac during the first quarter worth approximately $31,000. Two Sigma Advisers LP acquired a new stake in CureVac in the fourth quarter valued at approximately $48,000. Two Sigma Investments LP purchased a new stake in shares of CureVac in the fourth quarter valued at approximately $391,000. Finally, D. E. Shaw & Co. Inc. acquired a new position in shares of CureVac during the 4th quarter worth approximately $66,000. Institutional investors and hedge funds own 17.26% of the company’s stock.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.